Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as NNC0385-0434 G
NNC0385 · 1 trial · 1 indication
Measured in h \* nmol/L
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Participants will receive oral dose of NNC0385-0434 G tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 B tablet orally in the 5-day treatment period (period 2). |
| Sequence 2 | EXPERIMENTAL | Participants will receive oral dose of NNC0385-0434 G tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 F tablet orally in the 5-day treatment period (period 2). |
| Sequence 3 | EXPERIMENTAL | Participants will receive oral dose of NNC0385-0434 F tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 B tablet orally in the 5-day treatment period (period 2). |
| Sequence 4 | EXPERIMENTAL | Participants will receive oral dose of NNC0385-0434 F tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 G tablet orally in the 5-day treatment period (period 2). |
| Sequence 5 | EXPERIMENTAL | Participants will receive oral dose of NNC0385-0434 B tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 G tablet orally in the 5-day treatment period (period 2). |
| Sequence 6 | EXPERIMENTAL | Participants will receive oral dose of NNC0385-0434 B tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 F tablet orally in the 5-day treatment period (period 2). |
| Name | Type | Description |
|---|---|---|
| NNC0385-0434 G | DRUG | Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2). |
| NNC0385-0434 F | DRUG | Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2). |
| NNC0385-0434 B | DRUG | Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2). |
Inclusion Criteria: * Male * Aged 18-64 years (both inclusive) at the time of signing informed consent * Body mass index between 20.0 and 32.0 kilogram per meter square (both inclusive) * Considered to be generally healthy based on the medical history, physical examination, and the results of vital...
Top 12 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 4 | PHASE3 | Enlicitide |
| Novartis AG Sponsored ADR | NVS | 14 | PHASE3 | Inclisiran, Pelacarsen, DII235, QCZ484 |
| AstraZeneca PLC | AZN | 3 | PHASE3 | AZD0780, Laroprovstat, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 5 | PHASE3 | Plozasiran, zodasiran, VSA003 |
| Ionis Pharmaceuticals, Inc. | IONS | 2 | PHASE3 | Olezarsen, ION775 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE2 | Alirocumab |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Solbinsiran |
| MediciNova, Inc. | MNOV | 1 | PHASE2 | MN-001 |
| Verve Therapeutics, Inc. | VERV | 4 | PHASE2 | VERVE-102, VERVE-201 |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE1 | Obicetrapib |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| Esperion Therapeutics, Inc. | ESPR | 1 | - | Bempedoic acid+ Ezetimibe |
NNC0385 is an investigational small molecule developed by Novo Nordisk A/S for high cholesterol. It is in Phase 1 clinical development and has been studied in a single completed trial. It is not approved for any use, and it remains an experimental oral therapy rather than an available treatment.
NNC0385 is being developed for high cholesterol, a metabolic condition. The only completed study enrolled healthy male volunteers alongside a high cholesterol condition listing, so the program is still at an early research stage. No approved use for lowering cholesterol has been established for NNC0385.
NNC0385 is developed by Novo Nordisk A/S, the Danish pharmaceutical company whose shares trade under the ticker NVO. Novo Nordisk is the sponsor of the Phase 1 study of the compound. No partner or co-development arrangement for NNC0385 is part of the public program record.
NNC0385 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. Because it is investigational, NNC0385 is not FDA approved, and it has not moved beyond early-stage testing in humans.
NNC0385 has been studied in one completed Phase 1 trial, NCT05333107, titled a research study looking at new protein-based tablets in healthy men, oral formulation II. It enrolled 152 participants in the United States, was randomized and controlled, and included males aged 18 years and older.
Yes, NNC0385-0434 G is an alternative designation for NNC0385, the investigational small molecule from Novo Nordisk A/S being studied for high cholesterol. Readers searching either name are looking at the same Phase 1 compound and the same completed trial, NCT05333107.